Latest Headlines

  1. Mass General Brigham Launches Genetic Test Developed In Collaboration With Broad Clinical Labs To Predict Risk Across Eight Cardiovascular Conditions 9/3/2025

    In a step forward for genomic-driven preventive medicine, Mass General Brigham Personalized Medicine and the Massachusetts General Hospital's Cardiovascular Disease Prevention Center and Center for Genomic Medicine today announced the launch of an innovative genetic test designed to estimate an individual's inherited risk for eight chronic cardiovascular conditions.

  2. Arima Genomics Introduces Aventa Lymphoma Test To Resolve Diagnostic Uncertainty In B- And T-Cell Lymphomas 9/3/2025

    Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the broad commercial launch of the Aventa Lymphoma test at the Society of Hematologic Oncology (SOHO 2025) meeting in Houston, Texas.

  3. MicroGenDX's New Testing Platform Cuts NGS Turnaround Time To 24 Hours For Life-Saving Decisions 9/2/2025

    MicroGenDX, a national pioneer in molecular diagnostics, has incorporated Illumina's MiSeq i100 plus sequencing platform to reshape the future of infectious disease testing.

  4. Golden Helix And Genomenon Announce Strategic Partnership To Advance Clinical Diagnostics 9/2/2025

    Golden Helix, a global leader in clinical bioinformatics, today announced a strategic partnership with Genomenon to integrate its Mastermind Genomic Intelligence Platform and Cancer Knowledgebase (CKB) into the Golden Helix software suite.

  5. GeneseeqPrime® Gains FDA 510(k) Clearance 9/2/2025

    Geneseeq Technology Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for GENESEEQPRIME® NGS Tumor Profiling Assay, an in vitro diagnostic (IVD) test kit that uses next-generation sequencing (NGS) of DNA from FFPE tumor tissue to detect tumor gene alterations across a comprehensive multi gene panel in patients with solid malignant neoplasms.

  6. 3-Minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier Alzheimer's Diagnosis 9/2/2025

    Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, announced new research published in the journal Brain Communications, led by Dr. George Stothart, a cognitive neuroscientist based in the Department of Psychology at the University of Bath and Principal Scientist at Cumulus Neuroscience.

  7. QIAGEN Gains U.S. Clearance Of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access To Rapid Syndromic Testing 9/2/2025

    QIAGEN N.V. today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

  8. SeqOne Acquires Congenica To Create A Global Leader In AI-Powered Genomic Medicine 9/2/2025

    SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the prestigious Wellcome Sanger Institute.

  9. Otsuka Pharmaceutical Diagnostic Division Opens A New Laboratory In Tokyo To Advance Development Of Next-Generation Medical Devices 9/1/2025

    Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the establishment of a new research facility, the Tokyo Laboratory, located within the Mitsui Link Lab Shinkiba 2 Building in Koto-ku, Tokyo. The Tokyo Laboratory will serve as a new research base for Otsuka's Diagnostic Division.

  10. CARB-X Backs Neonatal Sepsis Diagnostic Platform By QuantaMatrix 8/28/2025

    Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded QuantaMatrix Inc.